OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in
Long Island, New York with facilities in Colorado, New Jersey and the United ...
May 14, 2013 ... OSI Pharmaceuticals became the home-grown beacon of Long Island, NY's
biotech scene behind the lung cancer drug erlotinib (Tarceva), ...
Agensys, Inc., a subsidiary of Astellas Pharma Inc. is developing a pipeline of
therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor
May 16, 2010 ... TOKYO and MELVILLE, N.Y. May 16 /PRNewswire-FirstCall/ -- Astellas Pharma
Inc. (TSE: 4503), a global pharmaceutical company, and OSI ...
May 17, 2010 ... Astellas Pharma (4503.T), Japan's No. 2 drugmaker, agreed to buy U.S. biotech
OSI Pharmaceuticals OSIP.O for $4 billion in cash in a ...
Jun 16, 2004 ... OSI Pharmaceuticals and Genentech Enter into Co-Promotion and Manufacturing
Agreements for Tarceva. Melville, N.Y. and South San ...
Jun 7, 2016 ... In the first False Claims Act settlement that turns on cancer-drug survival data,
Roche's Genentech unit and OSI Pharmaceuticals agreed to pay ...
Roche and OSI Pharmaceuticals to pay $67m to resolve claims they
misrepresented Tarceva effectiveness, diverting patients from first-line treatments
OSI Pharmaceuticals (Nasdaq: OSIP) and Gilead Sciences (Nasdaq: GILD) today
announced that they have signed an agreement, valued at up to $200 million ...
OSI's detailed financings; Comprehensive pipeline breakdown, including
molecular targets & partnerships. 17 years of in-depth BioPharma industry